Details of the Drug

General Information of Drug (ID: DMQZBXI)

Drug Name
Calaspargase pegol
Synonyms UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285
Indication
Disease Entry ICD 11 Status REF
Acute lymphocytic leukaemia 2B33.3 Approved [1]
Acute lymphoblastic leukaemia 2A85 Phase 3 [2]
Drug Type
Antibody
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-1.7 h [3]
Clearance
The clearance of drug is 0.147 L/day [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 16.1 days [3]
Vd
The volume of distribution (Vd) of drug is 2.96 L [4]
Cross-matching ID
DrugBank ID
DB14730
TTD ID
D0C9DA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Asparaginase (ASRGL1) TT4WT91 ASGL1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Calaspargase pegol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Calaspargase pegol and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [6]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Calaspargase pegol and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [7]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Calaspargase pegol and Pralsetinib. Lung cancer [2C25] [8]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Calaspargase pegol and Selpercatinib. Lung cancer [2C25] [8]

References

1 Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034060)
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
8 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]